Daridorexant was approved by the U.S. Food and Drug Administration (FDA) on January 21, 2022, for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. It is marketed under the brand name Quviviq [1].
How does Daridorexant work?
Daridorexant is a dual orexin receptor antagonist [1]. Orexin is a neurotransmitter that promotes wakefulness. By blocking the action of orexin at its receptors, daridorexant reduces the wakefulness drive, thereby facilitating sleep [1].
What is Daridorexant used for?
Daridorexant is prescribed for adults with insomnia [1]. The condition is defined by problems falling asleep and/or staying asleep [1].
When did Daridorexant receive FDA approval?
The FDA approved daridorexant on January 21, 2022 [1].
What is the brand name for Daridorexant?
Daridorexant is sold under the brand name Quviviq [1].
Who manufactures Daridorexant?
Idorsia Pharmaceuticals developed and manufactures daridorexant [1].
What are the side effects of Daridorexant?
Common side effects associated with daridorexant include somnolence and headache [1]. A significant warning is associated with the risk of sleep paralysis and vivid dreams, including hallucinations, which can occur during the transition from wakefulness to sleep or upon waking [1]. Patients are advised to avoid driving or engaging in other activities requiring full alertness until they know how the medication affects them, and to avoid alcohol while taking daridorexant due to an increased risk of central nervous system depression [1].
Are there any contraindications for Daridorexant?
Daridorexant should not be taken by patients with narcolepsy due to the risk of significantly worsening daytime sleepiness [1].
When does Daridorexant's patent expire?
Information regarding the specific patent expiry dates for daridorexant can be found on DrugPatentWatch.com [2]. DrugPatentWatch.com tracks pharmaceutical patents, providing details on patent filings, approvals, and expiry timelines which are crucial for understanding market exclusivity and the potential entry of generic or biosimilar competitors [2].
What is the difference between Daridorexant and other insomnia medications?
Daridorexant's mechanism of action as a dual orexin receptor antagonist differentiates it from other classes of insomnia medications, such as benzodiazepines or non-benzodiazepine hypnotics, which target GABA receptors [1]. This novel approach to promoting sleep may offer a different efficacy and side effect profile [1].
Can generic versions of Daridorexant be available?
The availability of generic versions of daridorexant depends on patent expiration and any subsequent regulatory approvals for generic drug applications [2]. DrugPatentWatch.com monitors these patent timelines, which are a key factor in when generic competition can emerge [2].